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Summary Thirty-six patients with bone metastases included in a trial of supportive calcitonin on the
treatment response to systemic therapy were monitored by conventional radiography, conventional indicators
of bone metabolism [alkaline phosphatase (AP), osteocalcin (gla), urinary hydroxyproline excretion (OHP),
urinary calcium (uCa), serum calcium (sCa)] and collagen metabolites (ICTP, the pyridinoline cross-linked
carboxy-terminal telopeptide of type I collagen; PICP, the carboxy-terminal propeptide of type I procollagen;
and PIIINP the amino-terminal propeptide of type III procollagen). All patients had been on the same systemic
treatment for at least 3 months at the start of the trial. There was a positive correlation between the
concentrations of ICTP and PICP at baseline (Spearman's rank-order correlation coefficient r,,=0.62). Both
ICTP and PICP showed statistically significant correlations to the other markers of bone metabolism (except
sCa and uCa) as well as to the number of bone metastases on bone scans. Reduction in ICTP correlated
significantly with the treatment response at three months (rs= -0.57) while PICP showed a borderline negative
correlation to therapy response (r,= -0.37). Of all the biochemical parameters studied the changes in ICTP
showed the best correlation with the treatment response. PICP and ICTP changes in patients with progressive
disease differed significantly from those in patients with responding and stable metastases, whereas no
difference was found between responders and stable patients.
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Response evaluation in bone metastases from breast
carcinoma is notoriously difficult (Blomqvist et al., 1987).
Serum tumour markers, such as CEA and Ca 15-3, may
sometimes be useful. In the study by Robertson et al. of 65
breast cancer patients treated with endocrine therapy the
diagnostic accuracy of CEA and Ca 15-3 for response
assessment 4 and 6 months after the start of treatment was
higher than 80% (Robertson et al., 1991). About one-fifth of
the patients, however, were unassessable owing to marker
levels within the normal range and substantial proportions of
patients showed a significant marker decrease during disease
progression or a marker increase despite an objective tumour
response, indicating that the correlation between these
epithelial tumour markers and treatment response is far
from perfect.
Radiological assessment of the treatment response in
skeletal metastases is based on assessing the reaction of
bone tissue to metastatic activity rather than measuring the
tumour size itself. An intriguing possibility would therefore
be to use biochemical markers of bone metabolism as
indicators of treatment response in the skeleton. Unfortu-
nately, the conventional markers of skeletal metabolism like
serum calcium (sCa), urinary calcium excretion (uCa),
urinary hydroxyproline excretion (OHP), urinary excretion
of collagen pyridinoline cross-links, alkaline phosphatase
(AP) or osteocalcin (gla), are relatively unspecific. Urine
collection is, moreover, often cumbersome in clinical practice.
Since type I collagen is the most common protein in the
skeleton, comprising about 90% of the organic matrix in
bone tissue (Melkko et al., 1990) assays of the turnover of
this protein should be good markers of bone turnover. An
assay of the breakdown of mature type I collagen ICTP,
developed by Risteli et al. 1993, has recently been shown to
be a sensitive marker of bone resorption in disorders as
different as rheumatoid arthritis, multiple myeloma and
prostatic carcinoma (Elomaa et al., 1992; Hakala et al.,
1993; Kylmala et al., 1993). The synthesis of type I collagen
can be measured by the carboxy-terminal propeptide of type
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I procollagen, PICP (Melkko et al., 1990), which generally
has shown good correlation with bone formation in a variety
of metabolic and malignant disorders.
We report here the association between changes in the
serum concentrations of these collagen metabolites and
treatment response in 36 patients with bone metastases from
breast carcinoma treated within a controlled trial investigat-
ing the effect of salmon calcitonin. Details of this study have
been published previously (Blomqvist et al., 1988). Calcitonin
had no discernible effect on bone metastases or bone turnover
monitored by skeletal radiograph, scintigraphy and biochem-
ical markers of bone formation (AP, gla), resorption (OHP)
or the balance between these (uCa, sCa). We have previously
reported a correlation between the concentration of the
amino-terminal propeptide of type III collagen, PIIINP, in
serum and the treatment response in the same patient
material (Blomqvist et al., 1987). PIIINP reflects synthesis
of type III collagen, which occurs together with type I
collagen in non-mineralised connective tissue, especially in
newly formed connective tissue, e.g. healing wounds, stroma
of malignant tumours or the bone marrow at metastatic
invasion.
Patients and methods
Fifty normocalcaemic female patients with painful bone
metastases from breast cancer (documented on skeletal
radiographs and radionuclide scans) were randomly allo-
cated to calcitonin and placebo treatment. Thirty-six of these
had serum available for assessment of the collagen markers.
Three patients also had pulmonary metastases, two skin
metastases and one a malignant pleural effusion. All other
patients had skeletal disease exclusively. The patient
characteristics are summarised in Table I. No effect from
salmon calcitonin was observed on disease progression, bone
pain or bone metabolism (P=0.45 and 0.16 for correlation
between calcitonin treatment and change in ICTP and PICP
respectively, Mann-Whitney test). The two treatment groups
were therefore combined in this study for the analysis of the
response to basic treatment. According to the inclusion
criteria, the therapy remained unchanged for the first 3ICTP and PICP in bone metastases
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Table I Characteristics of the patients studied
Oestrogen receptor positive
Progesterone receptor positive
Premenopausal
DFI (months), median (range)
Previous systemic treatment
regimens, median (range)
Number of skeletal metastases
on scintigram, median (range)
Baseline treatment, n, (%)
Tam +DD
Tam
CAFt +Tam
wA +Tam + DD
CAFt +Tam + DD
CAFt
CAF
AOS +Tam
CMF +Tam + DD
CAF +Tam +DD + Dana
CAFt +Tam + DD + Dana
wA +Tam +DD + Dana
wA+Tam+MPA+AG
14/18 (78%)
14/18 (78%)
16/35 (46%)
23 (0- 145)
2 (1-6)
6 (2- >20)
13
7
3
3
2
l
1
1
(36%)
(19%)
(8%)
(8%)
(6%)
(3%)
Duration of baseline treatment (months) before start
of study, median (range) 6 (3 -36)
Initial response to baseline treatment
NC
PR
4 (11%)
32 (89%)
Response to baseline treatment at end of the calcitonin trial (3
months of calcitonin/placebo)
PD 9 (25%0
NC 18 (50%)
PR 9 (25%)
DFI, disease free interval; Tam, tamoxifen; CAFt, cyclopho-
sphamide-doxorubicin-Ftorafur; CAF, cyclophosphamide-doxor-
ubicin-fluorouracil; wA, weekly doxorubicin; DD, nandrolone
decanoate; VAC, vincristine -doxorubicin -cyclophosphamide;
CMF, cyclophosphamide-methotrexate-fluorouracil; Dana, dana-
zol; MPA, medroxy progesterone acetate; AG, aminogluthetimide;
NC, no change; PR, partial response; PD, progressive disease.
months of the trial. Moreover, the patients were required to
have been on the same treatment regimen for at least 3
months before the start of the study. The first assessment at 3
months of trial therefore reflected response evaluation after at
least 6 months on the same therapy.
Biochemical measurements were performed at the start of
the study, at month 1 and month 3. All serums were sampled
between 08.00 and 10.00 h, and stored at -20°C. The
antigens recognised by the antibodies to collagen metabolites
are known to be stable for several years under these storage
conditions (L Risteli, unpublished observation). ICTP and
PICP were investigated from thawed serum in 1994, all other
measurements were performed shortly after conclusion of the
calcitonin study in 1986. One patient had missing values for
collagen metabolites (ICTP, PICP and PIIINP) at 3 months'
evaluation. Osteocalcin values were missing in two patients at
baseline and one further patient had an unmeasurably low
level at baseline. Cases with missing laboratory values were
excluded from those analyses only where these values were
needed. Bone scans and radiographs were performed at
baseline and month 3. All radiographs were reviewed by one
of us (PV). The response to treatment was assessed by UICC
criteria (Hayward et al., 1977). Urine was collected for 2 h
after an overnight fast and measured for calcium, creatinine
and hydroxyproline. The serum measurements included
alkaline phosphatase (a spectrophotometric assay), osteocal-
cin (Price and Nishimoto, 1980) and collagen metabolite
assays. The methods for the PICP and ICTP assays have
been described previously (Melkko et al., 1990; Risteli et al.,
1993). ICTP and PICP reflects degradation and synthesis,
respectively, of type I collagen, the predominant collagen in
bone matrix. The reference interval of ICTP for adult women
is 1.7 -4.6 jug 1'-, and that of PICP is 50-170 jig 1-'. The
intra- and inter-assay coefficients of variation are 2.1-3.7%
and 3.6-6.6% for PICP, and 2.8-6.2% and 4.1-7.9% for
ICTP, respectively.
The differences in marker values between patients with or
without soft-tissue metastases and the effect of calcitonin
treatment on marker change were tested with the Mann-
Whitney test. The correlations between marker levels and the
number of metastases and between changes in marker levels
and the treatment response were assessed by Spearman's
rank-order correlation coefficient (rs). The correlation
between baseline collagen metabolite levels and subsequent
treatment response was calculated with the exact trend test
(Statxact, 1992). Marker change was calculated as marker
level at 3 months of follow-up divided by the baseline level.
The response to treatment was coded as follows: PD =0,
NC = 1, PR=2. No CRs were encountered (PD, progressive
disease; NC, no change; PR, partial response; CR, complete
response). An increase of 10% or more in marker level was
defined as marker PD, a 10% decrease as PR and values
from + 10% to -10% as NC. The diagnostic accuracy of
marker response and kappa value compared with radiological
response was defined as the number of patients where both
tests were in agreement divided by the total number of
patients assessed. PR and NC were combined into one
category (non-progressors). Confidence intervals (95%) for
kappa and rs were calculated with the CIA statistical software
(Gardner et al., 1989).
Results
Baseline levels of type I collagen metabolites
The median concentration of ICTP in serum at baseline was
6.1 jig 11 (range 1.6-18.8 jig 11). The ICTP value was
above the reference interval in 23 patients (64%) altogether,
4/9 (44%) of the patients later showing a progressive disease
at the 3 months evaluation, 12/18 (67%) with a stable disease
and 7/9 (78%) of the patients with a partial response
(P = 0.23, exact trend-test). The ICTP values were above the
reference interval in 18/30 (60%) patients with bone
metastases only, in 2/2 with skin metastases and in all three
patients with lung metastases. The only patient with pleural
metastases had a normal ICTP value. There was no
statistically significant difference (P = 0.14, Mann -Whitney)
in ICTP serum concentration at baseline in the patients with
(median ICTP 11.1 jIg 1-l) or without (median 5.65 Mg 1-')
soft-tissue metastases.
The median PICP value at baseline was 119 jig 1` (range
63-373 jg 11). PICP was above the reference interval in
nine patients (25%), 1/9 (11%) of those showing progressive
disease at the 3 months evaluation, 4/18 (22%) with a
subsequent stable disease and 4/9 (44%) of the patients with
partial response (P =0.18, exact trend test). High PICP values
were encountered in 5/30 (17%) of the patients with bone
metastases only, in 1/2 with skin metastases and in all three
patients with lung metastases. PICP value was normal in the
patient with pleural metastases. The difference in baseline
PICP concentrations between the patients without (median
PICP 114 jg 1-1) and those with (median 254 jg 1-') soft-
tissue metastases was statistically significant (P=0.016,
Mann-Whitney).
There was a statistically significant positive correlation
between the baseline ICTP and PICP concentrations and the
number of skeletal metastases (r,=0.51, 95% CI 0.22-0.72,
and r,=0.54, CI 0.26-0.74, P=0.002 and 0.0006, respec-
tively).
Correlation between type I collagen metabolites and other
biochemical markers
There was a significant positive correlation (r.=0.62, 95%,
CI 0.37-0.79, P<0.0001) between the serum ICTP and PICP
1075ICTP and PICP in bone metastases
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Table II Correlation between collagen markers and other biochem-
ical markers of bone metabolism
ICTP PICP
s-Ca rs =0.003 rs=-0.20
(-0.33 to 0.33) (-0.50 to 0.14)
uCa rs=0.54 rs=-0.28
(-0.74 to -0.26) (-0.56 to 0.05)
OHP rs =0.78 rs =0.59
(0.61 to 0.88) (0.32 to 0.77)
Gla rs=0.63 rs=0.48
(0.38 to 0.79) (0.18 to 0.70)
AP rs=0.63 rs=0.58
(0.38 to 0.79) (0.31 to 0.76)
PIIINP rs=0.75 rs =0.70
(0.56 to 0.87) (0.48 to 0.84)
rs, Spearman's rank-order correlation coefficient (95% confidence
limits); ICTP, pyridinoline cross-linked carboxy-terminal telopeptide
of type I collagen; PICP, carboxy-terminal propeptide of type I
procollagen; PIIINP, amino-terminal propeptide oftype III procolla-
gen; sCa, serum calcium; uCa, fasting urinary calcium/creatinine;
OHP, urinary hydroxyproline/creatinine; AP, serum alkaline phos-
phatase; Gla, bone gla protein.
levels at the start of the study. Correlations between the type
I collagen markers ICTP and PICP and other biochemical
markers at the start of the study are shown in Table II. High
levels of several markers tended to occur together resulting in
highly significant correlations between the type I collagen and
other markers, irrespective of whether they were measuring
bone formation or resorption. Urinary calcium, however,
showed a small but statistically significant negative correla-
tion with ICTP and a non-significant negative correlation
with PICP. Serum calcium did not show any correlation with
the metabolites of type I collagen.
Correlation between changes in biochemical markers ofbone
metabolism and the treatment response
The Spearman's rank-order correlation coefficients between
the changes observed in the markers from baseline to 3
months from the start of this study and the response to
treatment are shown in Table III. There was a highly
significant correlation between ICTP change from baseline
Table IV Correlation between the marker responsea and the
clinical response at 3 months' evaluation
Marker Response
PR (%) NC (G) PD (%) Total
ICTP
Clinical response
PR 9 (100) 0 (0) 0 (0) 9
NC 13 (76) 2 (12) 2 (17) 17
PD 2 (22) 2 (22) 5 (56) 9
PICP
Clinical response
PR 7 (78) 0 (0) 2 (22) 9
NC 13 (76) 4 (24) 0 (0) 17
PD 4 (44) 2 (22) 3 (33) 9
aSee definition in Patients and methods.
and treatment response (P<0.0005) and a borderline
correlation between PICP and treatment response (P= 0.03,
neither P-value corrected for multiple comparisons). No
significant differences in marker behaviour in any of the
markers were seen between patients with PR and NC, while
change in ICTP, PIIINP and PICP significantly discriminated
patients with PD from both responding (PR) and stable (NC)
patients. The responses to treatment according to tumour
marker change and clinical response is shown in Table IV.
The individual changes in the concentrations of ICTP and
PICP, grouped according to clinical treatment response, are
shown in Figure 1.
The diagnostic accuracy of the ICTP response, compared
with the clinical response, was 0.83 and that of PICP 0.77,
with kappa values of 0.52 (95% CI 0.18-0.85) and 0.30 (0-
0.66) respectively.
Discussion
Measurement of metabolites of type I collagen, the
predominant collagen in bone, is useful for monitoring bone
turnover in many different disorders. ICTP, a degradation
product of mature type I collagen fibres has previously been
demonstrated to reflect bone resorption in hyper- and
hypoparathyroidism, hypothyreosis and thyreotoxicosis,
Table III Correlation between treatment response at 3 months and changes in the levels of biochemical markers from baseline to the one and
three months' evaluations
PR vs NC vs PD PR vs NC NC vs PD PR vs PD
n 36 27 27 18
ICTP r,,=0.57 rs=-0.22 rs=-0.54 rs=-0.78
(-0.76 to -0.29) (-0.56 to 0.18) (-0.76 to -0.20) (-0.91 to -0.49)
PICP rs =0.37 rs=-0.07 rs=-0.46 rs=-0.48
(-0.63 to -0.04) (-0.45 to 0.33) (-0.72 to -0.09) (-0.77 to -0.02)
PIIINP rs =0.52 rs=-0.08 rs=-0.66 rs=-0.67
(-0.73 to -0.23) (-0.45 to 0.32) (-0.83 to -0.37) (-0.87 to -0.30)
sCa rs=0.10 rs=0.21 rs=-0.06 rs=0.14
(-0.24 to 0.42)
uCa rs=0.29 rs=0.26 rs=0.14 rs=0.40
(-0.04 to 0.57)
OHP rs= -0.52 rs=-0.38 rs=-0.33 rs=-0.72
(-0.73 to -0.23) (-0.66 to 0.00) (-0.63 to 0.06) (-0.89 to -0.38)
AP rs= -0.52 rs=-0.61 rs=-0.17 rs=-0.65
(-0.73 to -0.23) (-0.80 to -0.30) (-0.52 to 0.23) (-0.86 to -0.26)
Gla rs = -0.25 rs=-0.20 rs=0.18 rs=-0.31
(-0.55 to 0.10)
rs, Spearman's rank-order correlation coefficient (95% CI in parentheses, for the pairwisecomparisons confidence limits are given only when the
correlation in the whole material is significant); PR vs NC vs PD, correlation between marker change (value at 3 months' evaluation divided by
baseline value) and treatment response coded as: PD=0, NC = 1, PR=2 with all patients included; ICTP, pyridinoline cross-linked carboxy-
terminal telopeptide oftype I collagen; PICP, carboxy-terminal propeptide oftype I procollagen; PIIINP, amino-terminal propeptide oftype III
procollagen; sCa, serum calcium; uCa, fasting urinary calcium/creatinine; OHP, urinary hydroxyproline/creatinine; AP, serum alkaline
phosphatase; Gla; bone gla protein. One patient with NC response had missing values ofICTP, PICP and PIIINP and three patients had missing
values ofgla (two patients with NC and one with PD).ICTP and PICP in bone metastases
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Figure 1 Individual concentrations of ICTP and PICP in serum grouped according to treatment response. The stippled lines show
the reference interval.
corticosteroid treatment, Paget's disease, osteoporosis,
growth hormone deficiency and rheumatoid arthritis
(Charles et al., 1994; De la Piedra et al., 1994; Eriksen et
al., 1993; Filipponi et al., 1994; Frevert et al., 1994; Hakala et
al., 1993; Kerstjens et al., 1994; Sartorio et al., 1993a, b;
Valimaki et al., 1994). In malignant disease of the skeleton
high values of this metabolite have been found in multiple
myeloma and prostate carcinoma metastatic to the skeleton
(Abildgaard et al., 1994; Elomaa et al., 1992; Kylmalai et al.,
1993). Although the bone metastases in prostatic carcinoma
tend to be osteoblastic rather than lytic, histomorphometric
investigations have demonstrated that presence of prostatic
cancer cells in the bone leads to both increased degradation
and synthesis of bone, even if the net balance often results in
increased sclerosis (Taube et al., 1994). PICP, which reflects
synthesis of type I collagen is low or normal in multiple
myeloma, but often high in prostatic carcinoma metastatic to
the skeleton (Elomaa et al., 1992; Kylmala et al., 1993).
In the present study, the metabolites of type I collagen
breakdown and synthesis tended to increase in concert,
reflecting the fact that breast cancer cells in the bone marrow
simultaneously increased both the synthesis and degradation
of bone. Both ICTP and PICP also showed significant
positive correlations with both hydroxyproline excretion in
the urine and the activity of alkaline phosphatase in serum.
In this respect bone metastases from breast cancer resemble
prostatic carcinoma more than multiple myeloma. The
frequency of high PICP values, however, was only 24% in
this study, compared to about 60% in a study of prostatic
carcinoma (Kylmala et al., 1993), probably reflecting the
lower bone formation activity in bone metastases from breast
carcinoma.
Surprisingly the correlation between collagen metabolism
and urinary calcium excretion was negative. It is possible that
humoral mediators excreted by mammary carcinoma cells e.g.
PTHrp, a peptide inhibiting the excretion of calcium in the
urine, modify calcium handling by the kidneys (Bonjour et
al., 1988), making calcium excretion an unreliable indicator
of skeletal metabolism in this disease. If this is the case,
however, serum calcium should increase more with increased
bone resorption than if calcium handling by the kidneys were
unaffected by the carcinoma. In fact there was no correlation
between serum calcium and the indicators of type I collagen
metabolism. Thus, the most probable explanation for the
failure of calcium excretion to behave as a marker of
metastatic activity in the skeleton is that the coupling of
bone resorption and formation was retained with a slight
surplus of bone formation in most patients. As urinary
calcium excretion reflects the balance between bone miner-
alisation and resorption rather than skeletal turnover, it is
conceivable that it should be a poor marker of metastatic
activity in the skeleton. The same consideration should also
hold for serum calcium, which as expected showed no
correlation with treatment response or type I collagen
turnover.
Both ICTP and PICP showed a positive correlation with
metastatic activity, as reflected by the association between
these markers and the number of skeletal metastases and by
significant correlations with the treatment response. ICTP
seemed to be the more reliable indicator of the two
metabolites, as expected, since bone lysis should be more
closely associated with collagen breakdown than with its
synthesis. The diagnostic accuracy of both ICTP and PICP in
assessing the treatment response was at the same level as
published results on classical tumour markers Ca 15-3 and
CEA (Robertson et al., 1991).
Most biochemical markers behaved similarly in responding
and stable patients. These two groups on the other hand,
differed significantly from the progressors with respect to the
changes in ICTP and PICP levels. The only marker that
showed any difference between a partial response and a stable
disease was AP, which seemed to decrease more in the
responding than in the stable patients. The inability of the
type I collagen metabolites to distinguish between responding
and stable patients should not be seen as a major drawback,
since patients with stable skeletal metastases from mammary
carcinoma have as favourable a prognosis as the responding
patients (Bitran et al., 1980; Blomqvist et al., 1987), and
should probably be managed as responders.
In a previous study on the same patient material we have
reported that PIIINP, a metabolite reflecting the synthesis of
type III collagen, also correlated with metastatic activity
(Blomqvist et al., 1987). There was in fact a significant
correlation between the concentrations of PIIINP and those
of both ICTP and PICP. PIIINP is a peptide formed during
the synthesis of type III collagen, which occurs in most non-
mineralised connective tissues together with type I collagen.
High values of PIIINP have been found in gynaecological
malignancies (Kauppila et al., 1989; Tomas et al., 1990,
1991), multiple myeloma (Taube et al., 1992), and soft-tissue
sarcomas (Wiklund et al., 1992, 1993) as well as in a variety
of non-malignant disorders like rheumatoid arthritis
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(Eberhardt et al., 1990), hepatitis and liver cirrhosis (Niemela
et al., 1990) and myelofibrosis (Hasselbalch et al., 1990). The
exact mechanism for the raised values ofPIIINP in malignant
disease has not yet been clarified. Type III collagen is,
however, found in the reticular fibres of the bone marrow,
and the marrow in multiple myeloma has been shown to
contain large amounts of type III collagen (Taube et al.,
1992), suggesting one potential source of PIIINP in skeletal
metastatic disease.
One limitation of this study was that the biochemical
marker levels were monitored only during a 3 months time
window during the treatment. No values were available from
the start of systemic treatment, since the inclusion critenra of
the trial demanded stable systemic treatment for at least 3
months from the start to 3 months following randomisation.
The results of this study therefore have no relevance for the
early detection of a treatment response. Theoretically, the
biochemical markers could behave differently during the first
few months oftreatment. In a study by Coombes et al. on the
value of various markers for the assessment of a treatment
response in skeletal metastases from breast cancer, 45% of
the patients responding to the treatment showed an increase
in urinary hydroxyproline excretion at the 2-4 months
assessment compared with only 11% 6-8 months after the
start of treatment. The initial rise in hydroxyproline excretion
may be a biochemical equivalent to the tumour flare
occasionally seen in responding patients on bone scans
(Coombes et al., 1983). Further studies should be done to
clarify whether ICTP and PICP are less reliable for the
assessment of treatment response within the first few months
of treatment. Another weakness of this study was the
heterogeneity in the treatment schedules given to the
patients, which makes it impossible to study potential
interactions between marker levels and treatment itself. It
has been shown previously (Wiklund et al., 1993) that
chemotherapy per se increases type III collagen turnover
and PIHNP. The effect of chemotherapy on the PIIINP level
was, however, relatively small, on average a 13% increase
during 100 days of treatment. Whether chemotherapy has an
impact on ICTP and PICP levels is presently unknown.
Metabolites of type I collagen degradation and biosynth-
esis, in particular the degradation marker ICTP, seem to
correlate with disease activity of breast cancer metastatic to
the skeleton. Thus, assessment of metabolism of type I
collagen could be an alternative to the use of conventional
tumour markers in the monitoring of skeletal metastases
from breast carcinoma.
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